Anti-Ofatumumab Polyclonal Antibody

Catalog No.

PAC90704

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

Ofatumumab

Tested applications

ELISA: 1:4000-1:8000

Target

Rabbit polyclonal to HuMax-CD20.

Specificity

The product is specific for Ofatumumab. This antibody serves as an excellent positive control for Ofatumumab immunogenicity (ADA) assays.

Concentration

0.5 mg/ml

Purification

Purified by antigen affinity column.

Accession

CAS: 679818-59-8

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.

Background

Ofatumumab (HuMax-CD20) is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes. And Ofatumumab is used to treat chronic lymphocytic leukemia and multiple sclerosis.

A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS)., PMID:40465056

Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis., PMID:40402264

Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis., PMID:40367683

Interventions for idiopathic steroid-resistant nephrotic syndrome in children., PMID:40337980

Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database., PMID:40235349

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies., PMID:40225374

Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis., PMID:40214505

The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function., PMID:40180777

Reconstitution of CXCR3+ CCR6+ Th17.1-Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis., PMID:40164501

Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A case report., PMID:40154217

Case Report: Efficacy of ofatumumab in refractory anti-NMDAR encephalitis: case series and literature review., PMID:40145095

Case Report: Ofatumumab treatment for concomitant multiple sclerosis and idiopathic thrombocytopenic purpura., PMID:40134425

Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model., PMID:40130187

Effective treatment of immune mediated peripheral neuropathy with Ofatumumab - A case report., PMID:40121773

Immune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study., PMID:40107181

Effect of Treatment on Steroidome in Women with Multiple Sclerosis., PMID:40076462

[Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis]., PMID:40047834

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis., PMID:39974306

Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis., PMID:39933126

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis., PMID:39917326

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system., PMID:39917308

Ofatumumab successfully treats myelin oligodendrocyte glycoprotein antibody-associated disease accompanied by Epstein-Barr viral infection: a case series., PMID:39845958

Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study., PMID:39835156

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice., PMID:39834277

Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis., PMID:39833702

Ofatumumab for treating autoimmune nodopathy., PMID:39800963

Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy., PMID:39787234

Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells., PMID:39774793

Ofatumumab-exposed breastfeeding in multiple sclerosis patients., PMID:39757874

Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches., PMID:39742715

Case report: paraneoplastic cerebellar degeneration associated with anti-Yo antibody successfully treated with ofatumumab., PMID:39737186

Ofatumumab treatment in new-onset narcolepsy type 1 following SARS-CoV-2 infection., PMID:39729629

Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials., PMID:39711787

Ofatumumab for multiple sclerosis with disability accumulation., PMID:39708694

Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy., PMID:39687682

The therapeutic effect of ofatumumab in pediatric anti-NMDAR encephalitis: A case series., PMID:39660186

Ofatumumab-associated colitis: A case report., PMID:39644146

Efficacy of ofatumumab combined with corticosteroids in the treatment of autoimmune encephalitis: a 6-month cohort study., PMID:39602016

Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab., PMID:39582359

Case report: The case report of ofatumumab, a fully human anti-CD20 monoclonal antibody, in the treatment of KLHL11 encephalitis., PMID:39575244

Impact of Continuous Ofatumumab Exposure During Pregnancy in Multiple Sclerosis., PMID:39524100

Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis., PMID:39515320

Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children., PMID:39513526

Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis., PMID:39388747

Profiling the impact of anti-human CD20 monoclonal antibodies on lymphocyte B cell subsets and their precursors in the bone marrow and in lymphoid tissues in an immunocompromised mouse engrafted with human cells., PMID:39374887

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials., PMID:39307151

Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset., PMID:39299183

Ofatumumab treatment for severe refractory anti-NMDAR encephalitis: A case series., PMID:39277986

B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease., PMID:39259430

Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis., PMID:39254048

Document Download

Anti-Ofatumumab Polyclonal Antibody.pdf